Pharmaceutical News

RSS

Amber Pharmacy receives ACHC accreditation

Amber Pharmacy announced today that it received accreditation by the Accreditation Commission for Health Care, Inc. (ACHC) for specialized pharmacy services.

4 Dec 2009

Watson Laboratories files an ANDA for generic version of Rozerem

Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 8mg ramelteon tablets prior to the expiration of a patent owned by Takeda Pharmaceutical Company Limited.

4 Dec 2009

IMF to stage presentation on multiple myeloma at ASH annual meeting

The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians—today said presentations at the annual meeting of the American Society of Hematology (ASH) will cover all stages of multiple myeloma, a major milestone in treating this and related cancers.

4 Dec 2009

DCVax therapeutic cancer vaccine manufacturing process receives patent approval

Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") announced today that the US Patent and Trademark Office has allowed its patent application on a system for automation of the initial stages of the manufacture of the Company's DCVax® therapeutic cancer vaccines.

4 Dec 2009

FDA approves once-daily SEROQUEL XR Extended Release Tablets

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD).

4 Dec 2009

New study shows seasonal flu vaccine awareness is high among Hispanics, but vaccination rates are lower

Although there is high awareness of the need for seasonal influenza vaccines, a new study of Hispanics in one California county shows low rates of actual vaccination, especially among men.

4 Dec 2009

GSK places a batch of AS03 adjuvanted H1N1 vaccine on hold

Following reports from Canada's Public Health Agency that six patients had suffered allergic reactions after receiving the shot, GlaxoSmithKline plc has voluntarily placed a hold on a single batch of the AS03 adjuvanted H1N1 vaccine Arepanrix in Canada as a precautionary measure.

4 Dec 2009

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed clinicians say they will use Amgen/GlaxoSmithKline's Prolia as either a second- or third-line therapy for osteoporosis if the drug receives regulatory approval for the indication.

4 Dec 2009

Cancer patient “Statement of Principles” brought to the 2009 ASH meeting

A coalition of cancer patient advocacy organizations led by the International Myeloma Foundation (IMF) and the MDS Foundation (MDSF), will bring its cancer patient “Statement of Principles” to the 2009 Meeting of the American Society of Hematology (ASH) in New Orleans December 5th through 8th.

4 Dec 2009

APCER Pharma Solutions' webinar on 2010 FDA drug safety and pharmacovigilance initiatives

APCER Pharma Solutions, Inc.’s webinar on 2010 FDA drug safety and pharmacovigilance initiatives gave more than 250 professionals in the life sciences-related industries the jump start they needed to prepare for important changes next year.

4 Dec 2009

Viral Genetics to develop drug therapies for immune-related disorders and diseases

The University of Colorado and Viral Genetics Inc., recently executed an exclusive license agreement that expands on its previous agreement allowing Viral Genetics to develop treatments for autoimmune diseases, graft rejection, HIV, and cancer based on the work of M. Karen Newell, Ph.D., a professor of biology at the University of Colorado at Colorado Springs.

4 Dec 2009

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Isis Pharmaceuticals, Inc. announced today that it has added two new drugs to its development pipeline, ISIS-FXIRx and ISIS-SMNRx.

4 Dec 2009

Two antimicrobial drug developing companies evaluate new approach for treating bacterial infections

Chaperone Technologies, Inc. and MerLion Pharmaceuticals Pte Ltd., both privately-held companies developing new antimicrobial drugs, announced today that they are together evaluating a unique approach for the treatment of resistant and life-threatening bacterial infections.

4 Dec 2009

Data from recent clinical trial for Caldolor Injection to be presented

Cumberland Pharmaceuticals Inc. announced today that data from a recent clinical trial for Caldolor® (ibuprofen) Injection, an intravenous treatment for pain and fever, will be presented at the 44th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting in Las Vegas, Nevada, in December.

4 Dec 2009

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

Gloucester Pharmaceuticals announced today that ISTODAX® (romidepsin) has been included in the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ as a suggested systemic treatment option for patients with mycosis fungoides and Sézary syndrome—two of the most common types of cutaneous T-cell lymphoma (CTCL).

4 Dec 2009

Wound Management Technologies to market CellerateRx within the U.S.

Wound Management Technologies, Inc., a rapidly growing provider of specialty medical products, announced today an agreement with the Health Industry Representative Association (HIRA) to serve as a non-exclusive independent sales and marketing representative to market the company's core CellerateRx® product within the U.S.

4 Dec 2009

Sulphonylureas, an antidiabetic drug, carries greater risk of heart failure and death compared to metformin

Research: Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database

4 Dec 2009

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Alkermes, Inc. and Acceleron Pharma, Inc. today announced that Alkermes has licensed a proprietary long-acting Fc fusion technology platform, called the Medifusion™ technology, which is designed to extend the circulating half-life of proteins and peptides.

4 Dec 2009

WHO investigates Tamiflu resistance, updates antiviral recommendations for H1N1 patients with severely compromised immune systems

Following recent reports of clusters of Tamiflu resistance, the WHO on Wednesday recommended that patients with severely weakened immune systems who become infected with the H1N1 (swine flu) virus receive additional antiviral treatment as needed throughout the duration of their illness, Agence France-Presse reports. "

4 Dec 2009

Update on European commercial launch of MuGard for oral mucositis provided

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.

4 Dec 2009

Pharmaceutical News

Amber Pharmacy receives ACHC accreditation

Watson Laboratories files an ANDA for generic version of Rozerem

IMF to stage presentation on multiple myeloma at ASH annual meeting

DCVax therapeutic cancer vaccine manufacturing process receives patent approval

FDA approves once-daily SEROQUEL XR Extended Release Tablets

New study shows seasonal flu vaccine awareness is high among Hispanics, but vaccination rates are lower

GSK places a batch of AS03 adjuvanted H1N1 vaccine on hold

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

Cancer patient “Statement of Principles” brought to the 2009 ASH meeting

APCER Pharma Solutions' webinar on 2010 FDA drug safety and pharmacovigilance initiatives

Viral Genetics to develop drug therapies for immune-related disorders and diseases

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Two antimicrobial drug developing companies evaluate new approach for treating bacterial infections

Data from recent clinical trial for Caldolor Injection to be presented

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

Wound Management Technologies to market CellerateRx within the U.S.

Sulphonylureas, an antidiabetic drug, carries greater risk of heart failure and death compared to metformin

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

WHO investigates Tamiflu resistance, updates antiviral recommendations for H1N1 patients with severely compromised immune systems

Update on European commercial launch of MuGard for oral mucositis provided

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News